Edition:
India

Stemline Therapeutics Inc (STML.OQ)

STML.OQ on NASDAQ Stock Exchange Capital Market

17.50USD
20 Apr 2018
Change (% chg)

$0.30 (+1.74%)
Prev Close
$17.20
Open
$17.10
Day's High
$17.50
Day's Low
$17.10
Volume
23,046
Avg. Vol
90,102
52-wk High
$18.75
52-wk Low
$7.30

Chart for

About

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the... (more)

Overall

Beta: -0.12
Market Cap(Mil.): $302.10
Shares Outstanding(Mil.): 25.28
Dividend: --
Yield (%): --

Financials

BRIEF-Stemline Therapeutics Inc - Co Launched An At-Market Offering Of Up To $50 Million Worth Of Shares

* STEMLINE THERAPEUTICS INC - ‍ON MARCH 16, 2018, CO LAUNCHED AN AT--MARKET OFFERING OF UP TO $50 MILLION WORTH OF SHARES OF COMPANY'S COMMON STOCK​ Source text (http://bit.ly/2HHHaYN) Further company coverage: (Reuters.Brief@thomsonreuters.com)

17 Mar 2018

BRIEF-Stemline Therapeutics Q4 Loss Per Share $0.93

* STEMLINE THERAPEUTICS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS

16 Mar 2018

BRIEF-Stemline Therapeutics Prices $51.8 Mln Public Offering

* STEMLINE THERAPEUTICS PRICES $51.8 MILLION PUBLIC OFFERING OF COMMON STOCK

24 Jan 2018

BRIEF-Stemline Therapeutics Announces Proposed Public Offering Of Common Stock

* STEMLINE THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

23 Jan 2018

BRIEF-Stemline Therapeutics reports Q3 loss per share $0.68

* Stemline Therapeutics reports third quarter 2017 financial results

10 Nov 2017

BRIEF-Stemline Therapeutics Inc - ‍phase 2 trial of SL-401 has met its primary endpoint​

* Stemline Therapeutics Inc - ‍phase 2 trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm has met its primary endpoint​

31 Oct 2017

Competitors

  Price Chg
Astellas Pharma Inc (4503.T) ¥1,582 -10.00
Eisai Co., Ltd (4523.T) ¥7,074 -19.00
Sumitomo Dainippon Pharma Co Ltd (4506.T) ¥2,016 0.00
Pfizer Inc. (PFE.N) $36.63 +0.10
Novartis AG (NOVN.S) CHF76.08 -1.20
Merck & Co., Inc. (MRK.N) $58.83 +0.19
Roche Holding Ltd. (ROG.S) CHF215.65 -0.85
Roche Holding Ltd. (RO.S) CHF220.00 -0.20
Sanofi SA (SASY.PA) €65.28 -0.32
GlaxoSmithKline plc (GSK.L) 1,430.00 +22.60

Earnings vs. Estimates